These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 34373964)

  • 21. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune checkpoint inhibitor-related hepatotoxicity: A review.
    Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
    World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
    Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
    J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
    Fan Y; Li S; Ding X; Yue J; Jiang J; Zhao H; Hao R; Qiu W; Liu K; Li Y; Wang S; Zheng L; Ye B; Meng K; Xu B
    BMC Cancer; 2019 Mar; 19(1):279. PubMed ID: 30922248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma.
    Lee BM; Seong J
    World J Gastroenterol; 2021 Mar; 27(10):919-927. PubMed ID: 33776363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Liver injury induced by immune checkpoint inhibitor-therapy : Example of an immune-mediated drug side effect].
    Straub BK; Ridder DA; Schad A; Loquai C; Schattenberg JM
    Pathologe; 2018 Nov; 39(6):556-562. PubMed ID: 30310977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathological features of immune-mediated hepatitis due to immune checkpoint inhibitors and anti-angiogenesis targeted therapy].
    Zhang QY; Chen LL; Gao F; Sujie A; Hou YY; Huang XW; Huang C; Sun HC; Zhou J; Ji Y
    Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):329-335. PubMed ID: 32268669
    [No Abstract]   [Full Text] [Related]  

  • 33. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma.
    Feng Z; Rong P; Wang W
    Gut; 2020 Oct; 69(10):1904-1906. PubMed ID: 31852768
    [No Abstract]   [Full Text] [Related]  

  • 34. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
    Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
    Front Immunol; 2020; 11():589997. PubMed ID: 33193421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
    Chen Z; Chen Y; Peng L; Wang X; Tang N
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection.
    Pandey A; Cohen DJ
    Immunotherapy; 2020 Apr; 12(5):287-292. PubMed ID: 32248723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma.
    Liu L; Qin S; Zhang Y
    Target Oncol; 2021 Mar; 16(2):153-163. PubMed ID: 33528759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma.
    Kuo HY; Chiang NJ; Chuang CH; Chen CY; Wu IC; Chang TT; Tsai HM; Lin YJ
    Oncol Res Treat; 2020; 43(5):211-220. PubMed ID: 32101878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.
    Brown ZJ; Heinrich B; Steinberg SM; Yu SJ; Greten TF
    J Immunother Cancer; 2017 Nov; 5(1):93. PubMed ID: 29157287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.